Years of research by world class scientists

Prof Siegel is a leading expert in methods that can rapidly and reliably discover novel enzyme catalysts, which has led to the discovery of enzymes with momentous functions including treating celiac disease and fighting anthrax infections. By leveraging breakthroughs form the field of synthetic biology, Prof Seigel’s research team are capable experimentally evaluating the properties of in silico designed proteins. His awards and honours include National Academies Education Fellowship, Alfred P. Sloan Research Fellowship and has served as the acting Director Innovation Institute for Food and Health, UC Davis.

Throughout his illustrious, 40 year research career, Prof German’s pivotal research has focused on improving foods and their ability to positively impact on health, using milk as the genetic blueprint for how foods can support health. During his career, he has been named to the Most Highly Cited Scientists List by ISI Index and has received honours including the president’s Award Canadian Federation of Biological Societies, John E Kinsella endowed chair University of California and Mention D’Honneur Du Jury ACADEMI MORIM.

Dr Chernoff carried out his medical training in UCSF and was Chief Resident of Internal Medicine at San Francisco General Hospital. He is a learned veteran of the molecular diagnostics industry, offering senior clinical leadership and key commercial input to organisations including Crescendo Bioscience, SetPoint Medical, Schiff Nutrition, Aquinox Pharma, Elan Pharma, NetScientific plc and Pulse Health, LLC. Durin his time as Medical Director of Chiron Corperation / Chiron Diagnostics, he played an instrumental role in the developing assays for HIV, HCV and CMV.

Nora is a mathematician with a PhD in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.

Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.

Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.

Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This groundbreaking find put into question many of the phylogenetic methods currently in use today.

Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.

Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.

Neil has 20 years of experience across a wide range of commercial functions in the food, nutrition and consumer health industries. He has been responsible for a number of global-first-to-market launches, including novel health-promoting ingredients via some of the world’s largest food manufacturers and consumer health CPGs; but also branded D2C products both through eCommerce and traditional bricks-and-mortar retail. Combining a degree in Nutritional Science with a business education from world renown Henley Business School, Neil’s fascination is the intersection of technology, food and genomics and how these will converge to disrupt the traditional (and failing) healthcare model.

Dr Sanja Trajkovic has a PhD in Analytical Chemistry, Masters in Physical Chemist and is a licenced toxicological chemist. With over 14 years in working in academic research and almost 10 years in industry, Sanja brings a wealth of experience to her role in Nuritas.
Prior to her PhD, Sanja worked in the National Centre for Poisoning Control in Serbia. She moved to the USA for her PhD in Analytical Chemistry at the University of Kentucky (UK). There Sanja applied molecular biology techniques for biomarker assay development. She also worked on a pipeline for qualitative and quantitative proteomics where she developed an array of novel strategies to apply state of the art bottom-up proteomic and mass spectrometry approaches to the PTM identification.
Sanja moved to Ireland in 2015 joining Alltech, where she built, from the ground-up, a new lab for mycotoxin testing and received ISO 17025 accreditation. She joined Nuritas in 2017 as Head of Proteomics and Analytical Science.

Alessandro has a wealth of experience in software development and machine learning. He started his career as a computer engineer in Sicily and moved to Dublin to get a PhD in Bioinformatics from UCD. His focus was on machine learning and predictive models for protein structure and function. He was one of the early employees in Nuritas, joining in its early stages in 2014. Alessandro has been instrumental in the development of the deep learning models for prediction of peptide bioactivities and properties. He has also been a key member in the development of the Nuritas software platform designed to follow the life-cycle of peptides from in-silico prediction to the market.

Ian has a PhD in immunology. With over 15 years’ experience in drug discovery and development, he has a wide range of therapeutic experience including transplantation and oncology. Brian’s post-doctoral work on proteins as potnential auto-immune therapeutics in Trinity College Dublin and this services as a basis for Opsona Pharmaceuticals Ltd.

Ian is a pharmacologist with a PhD in Cardiovascular Medicine. He has 10+ years of extensive scientific research experience and joined Nuritas from GSK where he led translational pharmacology and biomarker development.

Dr Aoife Doherty has a PhD in Bioinformatics and Molecular Evolution. She brings over 10
years of experience in scientific research. Before joining Nuritas, Aoife was a EMBO Long
Term Fellow in the Integrative Genomics of Ageing Group in the University of Liverpool.
There, she was the lead on an international collaboration between Liverpool and Duke
University that identified novel single nucleotide polymorphisms that differentially affect
mortality in cancer patients with age. This research is key in the development of age-
specific prognostic biomarkers and personalized therapies. She has also authored other
research on the role of gene expression changes, gene duplication patterns and a new
approach for interpreting random forest models.
Aoife joined Nuritas in 2017 and has been key in conceiving, developing and leading the
maintenance of a large, complex database of curated biological data. During her tenure, she
has overseen the amount of experimental information available to our proprietary
predictive platform to increase by >1000%.

Tim is an experienced drug discovery and development executive with over 25 years experience building successful teams, leading development programs, and participating in corporate strategy development and execution. He has led preclinical and clinical development organizations to multiple successful regulatory submissions including two that ultimately resulted in marketing approvals. He is also a licensed attorney with experience leading pharmaceutical asset and platform intellectual property portfolio development, providing legal counsel on all aspects of business operations, and with extensive experience in negotiating pharma-biotech partnership agreements.

Prior to joining Nuritas, Tim most recently served as Senior Vice President of Strategic Development at Recursion Pharmaceuticals, a privately held AI-enabled drug discovery company. At Recursion, Tim was a key contributor to the rapid growth of the company, led the company’s drug development programs bringing the company’s first compounds into the clinic, and previously served as Vice President of Business Development, Corporate Counsel, and IP Counsel. Tim also brings considerable therapeutic protein development experience to the company having worked extensively on parathyroid hormone and GLP2 programs as head of Clinical Operations at NPS Pharmaceuticals. Mr. Considine received a B.Sc. (Hons.) in Pharmacology from University College Dublin, and a J.D. with highest honors, from the S.J. Quinney School of Law at the University of Utah.

Andrew has a PhD in Neuropharmacology and 15+ years’ experience in drug discovery and development. He has worked on a wide spectrum of therapeutic indications including immunology, immune-oncology, cardio-metabolic disorders and central nervous system disorders. He has overseen 100+ Phase II and Phase II clinical trials.

Dr. Mark Gaffney has a PhD in Biotechnology and a tailored MBA from UCD Smurfit. He
brings over 17 years’ experience in R&D and industrial biotechnology. Mark’s previous
research has focused on the development and characterisation of novel ingredients for
the crop and agrifeed sectors. This largely revolved around the use of microbial-derived
components and peptide chelated minerals to deliver innovative solutions to the
marketplace, while enhancing the quality and nutritional value of foodstuffs. Prior to
joining Nuritas, Mark was in Alltech, where he held several positions, the last of which
was as Platform Lead for the Crop Science Research Programme.

Bernard Keogh has over 25 years’ experience in the technology and communications industries.

Prior to joining Nuritas, Bernard was a senior adviser at Granahan McCourt, a private investment firm focused on connecting people to innovation in technologically underserved areas of the world. He served as General Counsel of enet, the leading wholesale communications provider in Ireland, and sat on the boards of several other entities in which Granahan McCourt held investments.

Previously, Bernard held leadership roles with global communications firms Level 3 and Global Crossing. He was General Counsel at ComReg, regulator of the communications and postal sectors in Ireland, and held various roles at William Fry, a leading international law firm.

Arthur has more than 35 years of experience across a wide range of functional areas in the life sciences, pharma and biotech industries. He has been CEO of two early-stage life sciences companies in the medical device and drug discovery areas, and has led Global Marketing for Hospital Products at Merck and Millennium Pharmaceuticals’ Cardiovascular business unit. Over the last three years, he has provided business advisory, interim CEO, and commercial strategy consulting support for early stage companies in areas that range from neurodegenerative disease, oncology, and cardiovascular disease to obesity and synthetic biology. He holds a Bachelor’s Degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University, serves as Lecturer and faculty member of the Healthcare Ventures class and the IMPACT Innovation program at MIT. He is an avid scuba diver and underwater photographer, and has served in Advisory Board, fundraising, and business development capacities for a wide range of start-up and early stage companies in the Boston area.

Matthieu has over 25 years of experience in investment management with a concentration on Asian regions. Matthieu’s investment experience has been centred primarily on thematic investing where he has successfully identified specific themes and designed strategies to profit from them. In mid-2012, Matthieu started to explore the imbalance created by China in the world market of animal protein. He quickly became convinced that it was the tipping point of a multi-decade investment opportunity. In late 2013-early 2014, Matthieu decided to concentrate solely on this and founded New Protein Capital (NPC). The scope of investment of NPC has since been expanded to include the multiple challenges of the food and feed production processes.

Prior to founding NPC in 2014, Matthieu was with Everest Capital, a large independent investment firm with offices in the US and in Singapore, for over 16 years. At Everest Capital, he was a Senior Managing Director and the Director of Research as well as a member of the Executive and Investment committees. Prior to Everest, Matthieu was with Banque Paribas, in Hong Kong, New York, Taipei and Paris.

Matthieu has a postgraduate degree in Corporate Finance from Université Paris Dauphine and has a graduate degree from Institut d’Etudes Politiques de Paris (Sciences Po).

Nick Rosa is Co-founder and Managing Director of Sandbox Industries and Managing Director of Cultivian Sandbox. Nick serves as a Director or advisor to several companies, such as the Blue Cross Blue Shield Venture Fund, Healthbox Global Partners, Oncology Analytics, Nuritas, TechStars Chicago and The Chicago Innovation Awards.
Prior to forming Sandbox, Nick led the buyout and served as CEO of The NutraSweet Company. As a senior executive at Monsanto, he led the Nutrition and Consumer Products division, overseeing NutraSweet, the consumer Lawn and Garden Business, and Kelco food ingredients business. Nick also served as a Senior Vice President and Advisor to the Board of Directors at Monsanto.
Previously, Nick held senior executive positions at Searle and has experience with Masonite Corporation and Baxter. He has lived and worked in several countries, including Kuwait, Switzerland and France. Nick has also been involved with numerous civic and commercial organizations. Nick holds a B.S. in Political Science from Northern Illinois University and an MBA from DePaul University.